India is very much proud to be associated with Jawaharlal Nehru University (JNU), New Delhi media partner of just conducted International symposium on current of current Advances in Radiobiology, Stem Cells and Cancer Research (February 19-21, 2015).

The Networked Digital Library of Theses and Dissertations (NDLTD) has announced Jawaharlal Nehru University (JNU), New Delhi, India in partnership with the INFLIBNET Centre, Ahmedabad, India will be the host for the 18th annual symposium in 2015. This international conference on electronic theses and dissertations (ETDs) will be held for the first time in India.

Current understanding of risk associated with low-dose radiation exposure has for many years been embedded in the linear-no-threshold (LNT) approach, based on simple extrapolation from the Japanese atomic bomb survivors. Radiation biology research has supported the LNT approach although much of this has been limited to relatively high-dose studies. Recently, with new advances for studying effects of low-dose exposure in experimental models and advances in molecular and cellular biology, a range of new effects of biological responses to radiation has been observed. These include genomic instability, adaptive responses and bystander effects. Most have one feature in common in that they are observed at low doses and suggest significant non-linear responses. These new observations pose a significant challenge to our understanding of low-dose exposure and require further study to elucidate mechanisms and determine their relevance.

It also discussed emerging trends in cancer stem cells, therapeutic targeting of cancer stem cells, novel mechanisms in cancer chemoprevention, development of phytopharmaceuticals for cancer chemoprevention and therapy, genetic and epigenetic mechanisms in the pathobiology of cancer, and advances in basic and translational cancer research.”

Here’s an editorial titled Cancer Biology: Pre-clinical to Translational Research I wrote for the abstracts book of the conference:

In November 2014, Nature featured a body of work (1, 2, 3, 4, 5) extending the list of cancers that might respond to anti-tumor immunity restoration therapies by blocking the PD-1 pathway.

Experiments also showed how expression of PD-L1 on immune cells infiltrating tumors could be a key predictor of clinical activity2, 3. A couple of findings4, 5 suggested that ‘passenger’ mutations — cancer-cell mutations that do not directly contribute to cancer initiation and progression — play a key part in tumor immunity.

The significance of cancer research can never be enough, the International Conference on Current Advances in Radiobiology, Stem Cells and Cancer Research is promising to give us some significant take homes. These three key areas expected to showcase results of new experiments from the world over.